cjc-1295 gh-stack growth-hormone

CJC-1295 + Ipamorelin: The Gold Standard GH Stack, Explained

April 22, 2026 · Updated May 17, 2026

CJC-1295 and Ipamorelin together drive 2-3x the growth hormone output of either compound alone — because they activate two completely independent receptor pathways on the same pituitary cells. Every serious GH research protocol ends up at this pairing. Not because it is fashionable. Because it is the only combination that hits both arms of the GH-release machinery simultaneously without introducing hormonal confounders.

The Quick Read

CJC-1295 → GHRH analog. Raises GH gene transcription. Sustained baseline elevation. Sets the stage.
Ipamorelin → GHRP. Triggers pulsatile GH release from existing stores. Clean — no cortisol, no prolactin, no appetite spike.
Together → synergistic 2-3x GH release. Pulse amplitude on elevated baseline. Pulsatility preserved. No hormonal confounders.
Both → ≥99% HPLC-verified at Ki. Research use only.

Why this stack matters

The somatotrophs in the anterior pituitary have two doors. CJC-1295 opens one. Ipamorelin opens the other. Open them at the same time and the GH release event is not additive — it is multiplicative. That synergy is the entire point of the stack, and it has been replicated across decades of research since Bowers et al. first established it in 1990.

Run either peptide solo and you only get half of the available machinery. Run them together — on protocol-aligned timing — and you maximize physiological GH output without breaking the body's feedback loops. That is why this pairing has been the backbone of GH secretagogue research for over thirty years.

Need the prerequisite primer on GHRH vs GHRP? Start with GHRH vs GHRP: Understanding Growth Hormone Peptide Research.

The Two Peptides, in Thirty Seconds

CJC-1295 is a GHRH analog — a modified 30-amino-acid fragment of the body's natural growth hormone releasing hormone. Strategic amino acid substitutions at positions 2, 8, 15, and 27 make it resistant to DPP-IV enzymatic cleavage, extending its functional half-life from roughly 7 minutes (native GHRH) to several hours.

Ipamorelin is a GHRP — a synthetic pentapeptide that mimics ghrelin at the GHS-R1a receptor. It is the cleanest GHRP available. Unlike older compounds in its class (GHRP-6, GHRP-2, Hexarelin), it stimulates GH release without touching cortisol, ACTH, prolactin, or appetite.

The two compounds do not compete. They cooperate. That is the whole point of running them together.

The Synergy: Why 1 + 1 = 2.5 (or 3)

The somatotroph cells in the anterior pituitary express two distinct receptors relevant here. GHRH-R, which CJC-1295 binds. And GHS-R1a, which Ipamorelin binds. Each receptor drives a completely different intracellular signaling cascade.

GHRH-R (CJC-1295): Activates adenylyl cyclase. Raises intracellular cAMP. Triggers the PKA pathway. This drives GH gene transcription — the cell starts producing more GH protein — and opens voltage-gated calcium channels on the cell membrane to allow extracellular calcium influx.

GHS-R1a (Ipamorelin): Activates phospholipase C. Generates IP3 and DAG. Releases calcium from intracellular stores in the endoplasmic reticulum. Activates protein kinase C. This drives immediate exocytotic release of pre-formed GH granules — a fast GH pulse from the existing store.

The two cascades converge at intracellular calcium mobilization. CJC-1295 raises calcium from the outside. Ipamorelin raises it from the inside. When both sources fire simultaneously, the calcium spike is much larger than either alone — which drives a much larger exocytotic event. More GH granules fused to the membrane. More GH released per pulse.

Bowers et al. (1990), published in the Journal of Clinical Endocrinology & Metabolism, established this synergy nearly 35 years ago. Co-administration of GHRH with a GHRP produced GH release approximately 2-3x greater than either compound alone — a finding replicated across multiple studies and peptide combinations in the decades since.

There is a second layer. GHRPs partially suppress somatostatin signaling (Tannenbaum et al., 2003, Endocrinology), creating a more permissive environment for GHRH to act. And GHRH, by upregulating GH gene transcription, replenishes the releasable GH pool so the pituitary does not deplete as Ipamorelin drives larger pulses. The two peptides support each other.

What the Published Research Shows

CJC-1295's Baseline Contribution

The landmark study on CJC-1295 is Teichman et al. (2006), published in the Journal of Clinical Endocrinology & Metabolism. A single administration produced a 10-fold increase in GH secretion and a 2-3-fold elevation in IGF-1 sustained for up to 6 days. The compound preserved normal GH pulsatility — meaning the body's physiological GH rhythm remained intact while total output rose substantially.

This is the baseline Ipamorelin gets stacked on top of. Somatotrophs primed. GH gene transcription elevated. IGF-1 climbing.

Ipamorelin's Amplification

Raun et al. (1998), published in the European Journal of Endocrinology, established Ipamorelin as the first selective growth hormone secretagogue. Ipamorelin demonstrated dose-dependent GH release equivalent to GHRP-6 in animal models — but with no significant effect on ACTH, cortisol, prolactin, or TSH. That selectivity is what allows researchers to add Ipamorelin to any protocol without introducing confounding hormonal variables.

Layer Ipamorelin on primed somatotrophs and you get large pulsatile GH release events without the cortisol elevation that would compromise the anabolic, recovery, and body composition endpoints the research is measuring.

The Combined Effect

Sackmann-Sala et al. (2009) and subsequent work consistently replicated Bowers' original finding: co-administration of GHRH analogs with ghrelin mimetics produces GH release roughly 2-3x greater than either compound alone. This is not a narrow, fragile effect — it is robust across species, protocols, and specific compound combinations. The CJC-1295 + Ipamorelin pairing inherits this synergy and layers Ipamorelin's unique selectivity profile on top.

Head-to-Head: Solo vs Stack

Endpoint	CJC-1295 solo	Ipamorelin solo	CJC-1295 + Ipamorelin
GH release magnitude	Sustained elevation, moderate peaks	Sharp pulses, moderate amplitude	Sharp pulses on elevated baseline, 2-3x larger peaks
GH gene transcription	Strongly upregulated	Minimal effect	Strongly upregulated (via CJC-1295)
IGF-1 elevation	Sustained, robust	Transient, smaller	Sustained + pulse-driven, largest
Pulsatility preservation	Yes	Yes	Yes
Somatostatin handling	Suppressed by it	Partially overrides it	Overridden + worked around
Cortisol / prolactin	No effect	No effect	No effect
Recovery / lean mass endpoints	Moderate	Moderate	Largest (in preclinical models)
Sleep architecture research fit	Good	Good (nocturnal pulse)	Best (amplifies natural nighttime pulse)

The solo versions are valid research tools for specific questions — CJC-1295 alone for studying sustained GHRH-R activation, Ipamorelin alone for isolating GHS-R1a pharmacology. But for researchers asking "how large can physiological GH output be driven while preserving pulsatility and avoiding hormonal confounders," the stack is the tool that actually answers the question.

Why This Stack Dominates the Research Literature

Three reasons.

First — the mechanism stacks cleanly. Because GHRH-R and GHS-R1a activate independent cascades, there is no receptor competition. The peptides do not antagonize each other. They both do exactly what they do alone — only now they do it simultaneously on the same cells.

Second — Ipamorelin's clean profile means the stack has no hormonal confounders. Pair CJC-1295 with GHRP-6 instead and you still get synergistic GH release — but you also get cortisol elevation, prolactin elevation, and (with GHRP-6) appetite changes that would confound any downstream measurement. Ipamorelin eliminates those variables while preserving the synergy. This is why Ipamorelin is the GHRP of choice for serious research protocols.

Third — the stack preserves physiological pulsatility. Both peptides work through the body's own signaling architecture. Neither delivers supraphysiological boluses the way exogenous recombinant GH does. The pituitary still receives somatostatin inhibition, still follows its circadian rhythm, still self-regulates. The stack amplifies what the body already does — without breaking the feedback loops that keep GH release physiological. For translational research, that distinction matters enormously.

Research Applications Where the Stack Is the Default Choice

Body composition research. GH and IGF-1 drive lipolysis and support lean tissue maintenance. The combined pulse-plus-baseline GH signal from the stack is particularly well-suited to body composition endpoints requiring sustained anabolic signaling without acute cortisol spikes. For researchers specifically interested in visceral adipose tissue reduction, Tesamorelin is the GHRH analog with the strongest published data — see Tesamorelin & Visceral Fat: What the Phase III Data Actually Shows.

Recovery and tissue repair research. GH/IGF-1 elevation supports protein synthesis, collagen synthesis, and cellular repair — making the stack a common inclusion in research designs involving musculoskeletal injury, post-exertion recovery, and tissue remodeling. Frequently layered alongside BPC-157 and TB-500 for comprehensive coverage — see BPC-157 vs TB-500 for the recovery-peptide companion piece.

Sleep architecture research. The largest physiological GH pulse of the day occurs during early slow-wave sleep. The CJC-1295 + Ipamorelin stack specifically amplifies this natural nocturnal pulse, making it a useful tool for investigators studying GH-sleep interactions and slow-wave sleep quality.

Age-related GH axis research. GH secretory amplitude declines measurably with age even as pituitary GH stores remain adequate. The stack is frequently used in aging models because it restores GH output through the natural axis rather than bypassing it with exogenous GH — a mechanistically cleaner intervention for answering aging-specific research questions.

Stack Design Considerations

Pulse Timing Relative to Circadian Rhythm

Endogenous GH pulses follow a predictable circadian pattern, with the largest amplitude pulse occurring during early slow-wave sleep. Research protocols frequently align CJC-1295 + Ipamorelin administration with this natural pulse rather than against it — the thinking being that stacking the synthetic signal onto the endogenous signal maximizes total GH output without fighting somatostatin troughs.

The "No DAC" Distinction Matters

CJC-1295 exists in two forms. The no-DAC version (Modified GRF 1-29 — what Ki Peptides carries) produces pulsatile GH release compatible with Ipamorelin's pulse-amplification mechanism. The "with DAC" version covalently binds serum albumin for an ~8-day half-life and produces sustained, flat GH elevation — which many researchers consider non-physiological and which does not stack as cleanly with a pulsatile GHRP like Ipamorelin. For stack research, no-DAC is the default. See the CJC-1295 product page for the full structural breakdown.

The Alternative: Tesamorelin + Ipamorelin

Researchers who want the full-length GHRH structure and the strongest clinical pedigree sometimes substitute Tesamorelin for CJC-1295. Tesamorelin retains all 44 amino acids of native GHRH and has Phase III clinical trial data — including the Falutz et al. (2007) New England Journal of Medicine study on visceral adipose tissue reduction. The synergistic mechanism is identical; only the GHRH backbone is different. This pairing is common in metabolic and body composition research where Tesamorelin's clinical validation is an asset.

Purity and Research-Grade Sourcing

The entire rationale of the stack falls apart if the peptides are impure. Contaminants and truncated sequences do not contribute to the synergy — they just add noise to downstream measurements. Both peptides in this stack should be HPLC-verified at ≥99% purity with a Certificate of Analysis per batch. Ki Peptides ships CJC-1295 at ≥99% and Ipamorelin at ≥99.6%, both third-party tested. For the deeper reasoning, see Peptide Purity: Why ≥99% Matters.

Frequently Asked Questions

Why is CJC-1295 + Ipamorelin considered the gold standard GH peptide stack?

The pairing activates two independent receptor pathways — GHRH-R (cAMP/PKA) via CJC-1295 and GHS-R1a (PLC/IP3/PKC) via Ipamorelin — on the same pituitary somatotrophs. Because the pathways converge on intracellular calcium mobilization from two different sources, co-activation drives a much larger exocytotic GH release event than either peptide alone. Bowers et al. (1990) established this synergy at approximately 2-3x the GH output of single-peptide administration, and the finding has been replicated across decades of research. Ipamorelin's selectivity profile (no cortisol, prolactin, or appetite effects) means the stack delivers the synergy without hormonal confounders — which is why it has become the default.

Is there a meaningful difference between CJC-1295 no DAC and CJC-1295 with DAC for stacking?

Yes. CJC-1295 no DAC (Modified GRF 1-29) produces discrete pulsatile GH release compatible with Ipamorelin's pulse-amplifying mechanism. CJC-1295 with DAC covalently binds serum albumin for an approximately 8-day half-life and produces sustained, non-pulsatile GH elevation — which many researchers consider non-physiological. For stacking with a GHRP, no DAC is the standard choice. Ki Peptides carries the no-DAC form.

Does this stack suppress natural growth hormone production?

No. Both peptides work through the body's native signaling pathways — amplifying endogenous GH release rather than bypassing the pituitary. Exogenous recombinant GH does suppress natural production via negative feedback on the hypothalamic-pituitary axis. The CJC-1295 + Ipamorelin stack preserves somatostatin feedback, preserves pulsatility, and preserves the HPA axis. This is a core mechanistic difference between secretagogue stacks and exogenous GH research.

How does this stack compare to running either peptide alone?

Solo CJC-1295 delivers sustained GHRH-R activation with elevated baseline GH and IGF-1 but without sharp pulses. Solo Ipamorelin delivers clean pulses but without the underlying GH gene transcription upregulation. The stack combines both: elevated baseline + sharp pulses + sustained IGF-1 + clean hormonal profile. For research endpoints that depend on total GH exposure (body composition, IGF-1 kinetics, recovery), the stack typically produces the largest effect.

Can Ipamorelin be stacked with other GHRH analogs like Tesamorelin?

Yes. The synergistic mechanism depends on the pairing of any GHRH-R agonist with any GHS-R1a agonist — it is not specific to CJC-1295. Tesamorelin + Ipamorelin is a common research pairing, particularly in metabolic and body composition research where Tesamorelin's Phase III data on visceral adipose tissue is an asset. The mechanism is identical; the choice between CJC-1295 and Tesamorelin comes down to structural preference (truncated vs full-length GHRH) and which clinical evidence base is most relevant to the research question. See Tesamorelin & Visceral Fat for the Tesamorelin-specific deep dive.

Does Ipamorelin's ceiling effect apply to the stack?

Ipamorelin exhibits a dose-dependent ceiling effect — GH release increases with dose up to a saturation point, beyond which additional peptide does not produce more GH. Within the stack, the ceiling still applies to the Ipamorelin-driven pulse component. What CJC-1295 adds is GH gene transcription upregulation, which increases the size of the releasable pool that Ipamorelin can trigger release of. So CJC-1295 effectively raises the ceiling by making more GH available for Ipamorelin to pulse out. This is a mechanistic reason the two stack so well: each peptide compensates for the other's limitation.

What purity should researchers require for both peptides?

For reproducible results, both peptides should be HPLC-verified at >=99% purity with batch-specific Certificates of Analysis and endotoxin screening. Sub-99% material introduces truncated-sequence contaminants and residual synthesis impurities that can confound downstream measurements — particularly problematic in a synergistic stack where the clean receptor selectivity of Ipamorelin is part of the point. Ki Peptides ships both peptides third-party tested at research-grade purity.

Are these peptides for human therapeutic use?

No. CJC-1295 and Ipamorelin are sold strictly as research peptides for preclinical and in vitro investigation. Neither is FDA-approved for human therapeutic use. All study references in this article refer to research models — human clinical studies cited were conducted under regulatory protocols that do not extend to commercial peptide sales. Ki Peptides products are intended for research use only.

Sources

Bowers, C.Y., Momany, F.A., Reynolds, G.A., & Hong, A. (1990). On the actions of the growth hormone-releasing hexapeptide, GHRP. Journal of Clinical Endocrinology & Metabolism, 71(6), 1526-1531.
Teichman, S.L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.P., & Frohman, L.A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
Raun, K., Hansen, B.S., Johansen, N.L., Thogersen, H., Madsen, K., Ankersen, M., & Andersen, P.H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
Sackmann-Sala, L., Ding, J., Frohman, L.A., & Kopchick, J.J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477.
Tannenbaum, G.S., Epelbaum, J., & Bowers, C.Y. (2003). Interrelationship between the novel peptide ghrelin and somatostatin/growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion. Endocrinology, 144(3), 967-974.
Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359-2370.
Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J.P., Frohman, L.A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism, 291(6), E1290-E1294.
Johansen, P.B., Segard, H.B., Grosen, E., & Flyvbjerg, A. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113.
Veldhuis, J.D., Keenan, D.M., & Pincus, S.M. (2005). Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis. American Journal of Physiology - Endocrinology and Metabolism, 289(6), E1027-E1035.

All compounds referenced are sold strictly for research use only. Ki Peptides does not sell products for human consumption, and no statements on this page have been evaluated by the FDA. Consult applicable regulations in your jurisdiction before purchasing.